Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 10/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA4 | P22748 | 6/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792114 | 0.93 | CCNA2 (0.50) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL6790709 | 0.88 | CCNA2 (0.49) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL6791972 | 0.86 | ALDH1A1 (0.53) | CA1CA2CCNA2CDK2CCNA1 | |
| SCHEMBL6793005 | 0.86 | CCNA2 (0.65) | CCNA2CDK2CCNA1RAD52KDM4E | |
| SCHEMBL5258632 | 0.85 | PTGS2 (0.52) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL5254020 | 0.85 | CCNA2 (0.50) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL6660718 | 0.81 | CA9 (0.55) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL6352140 | 0.81 | RAD52 (0.56) | CA9CA1CA2CA4CCNA2 | |
| Hydrochloric Acid SCHEMBL6800512 | 0.80 | PTGS2 (0.51) | CA9CA1CA2CA4CCNA2 | |
| SCHEMBL6793613 | 0.80 | CCNA2 (0.52) | CA9CA1CA2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| EP-1476431-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1427706-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003070706-A1 | TRICYCLIC PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003024936-A1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | CA9 2086/4885CA1 3517/4885CA2 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.